They’re not shorting a cancer treatment. They’re betting against our ability to commercialise before we go for more cash.
They’ll likely lose. Especially form this level. Seems an odd move. We should be long past this rubbish… the tiring attitude of the CEO comes to pass once more.
Energy - best post in a while. Perfectly framed.
Primary source is a handful of tweets (literally) that have been interacted with by a load of AVCT SHs. In nowhere indicative of interactions with deal makers in AACR.
But Affimers have several advantages over Mabs and aptamers… apart from earning any cash.
PL - yes, many have presented similar results in terms of AEs. Key point to note, the unicorn is how effective they were at said AEs.
IMO, the AE profile and PKs suggest a stop at Q3W C4 does. Maybe 5 at a push.
Lots of words there eggy. I’ll not engage, you’re a scourge.
The CEO is the guy guiding the investment we’ve all made. And he’s made an atrocious decision to buy a very basic/non disruptive Dx business that’s haemorrhaging money. Not all his his fault, as I’ve previously stated - HCI will have mandated it as part of the CLN.
It’s fair to be annoyed by the constant noise around the AS bashing. I’m part of that problem. And try and refrain in the main. PL is really mild if you ask me. But I’m too quite miserable!
It’s a bit of a shame to see solid posters at odds, when they’re all here for the same thing. Unlike some others that are actually trolls.
3 months til the AGM. AS will be judged then. Dx numbers will be available. Data may well have commercialised something. Until then, no news, sit on hands.
Heights required the Dx purchase to underpin the loan. Clinical data had no impact. As eggy says - hard of me to admit - is correct re share price sales at a discounted purchase price.
Easy money. They’re a loan shark. One up from those you see on the box.
Apre - you’re better than interacting with a charlatan.
He’s a crook that spent 3 years fluffing the CEO SBTX alongside TW. Both have a crappy paid for email newsletter (mental in 2024 people pay to be spammed).
SBTX has finally imploded. Leaving this account to wander. Is it TW? Not sure. But his unwavering support of SBTX, despite an awful CEO is telling. That said, SBTX recently took out a CLN and this spelled the end of their love affair.
In summary - a TW dupe charlatan.
You’re missing the point. He’s happy to shout, then patronise with an orders lower number when he’s nabbed his salary.
Actually amazed that the crowd has flipped and he’s now again a messiah.
It was his most waffally piece yet. We’re here for cash. The deals he quoted last year we weren’t to worry about are no longer being considered as we ‘know the value of precision’ but still said he’d done no work to quantify that value when asked the direct question?!
Just another can kicked unfortunately. CC was fantastic and the data is brilliant. He still needs to go.
The only thing left is the old LFT comparison.
Eggy is gutted those with Arthritis will now be allowed on the trial do the superb targeting of active FAP.
There really is no other angle left. The LFT. Wow.
The RNS changed lots. It’s the first time we’ve seen the data categorised in such a way. First time we’ve seen the data tell us, in no uncertain terms that solvable FAP is not the enemy eggy would have us believe. Like, a load of nonsense.
What a great RNS.
Blocked. Can’t take this crap about Dx rubbish any longer.
Whoever goes, please pick up a brochure.
Haha
We were promised the full release. Yet we won’t be given it. Very simple u turn by AS. Again.
It’s not full data. We’ll never get that unfortunately- as PL says, it’s a riddle that’ll never fully unwind. We’ll get it in chunks to satisfy his disregard for those who pay his wages.
Nevertheless, more is welcomed. Another reason we’ll NEVER move to NASDAQ while he’s there.
David Wilson earning his crust. Nice to see.